Navigation Links
Lupus Foundation of Florida Applauds Support for Biosimilars Legislation
Date:4/3/2013

TALLAHASSEE, Fla., April 3, 2013 /PRNewswire-USNewswire/ -- The Lupus Foundation of Florida applauds the Health Policy committee of the Florida Senate for the passage of Senate Bill 732 out of committee.  The legislation will allow biologic medicines to be automatically substituted with interchangeable biosimilar medicines by pharmacists.  It would also ensure doctors are made aware of product substitution and ensure records of biosimilar substitution are kept for a reasonable amount of time.

"As a patient advocate, I overwhelmingly support this bill, which sets guidelines for safely introducing biosimilar drugs into the Florida pharmaceutical market," said Linda Reucher , Program Director of The Lupus Foundation of Florida. "Senator Grimsley's bill supports transparency of our healthcare system and provides the most vulnerable Floridians – the elderly and chronically ill – affordable access to these life-changing medications.  The bill will also ensure that doctors and their patients have the most accurate information available, which ensures the highest standard of medical care."

The Food and Drug Administration will likely approve biosimilars in the next year or two and they will soon be made available to patients.  Setting up a framework for patients to access biosimilars at pharmacy counters and ensuring the safe substitution and tracking of these highly complex products now – rather than down the road – makes sense.

As the name indicates biosimilars are similar, though not exact copies of their reference biologic product, and so even miniscule changes between a biologic and its biosimilar products might affect lupus patients and other patients taking biologic medicines.

There are approximately 1.5 million Americans with lupus and 90,000 in the state of Florida. When lupus fails to respond to traditional treatment methods, lupus patients may be prescribed biologics, particularly Rituxan and Benlysta. This is quite common in lupus nephritis which affects about half of all lupus patients.

About the Lupus Foundation of Florida
Since 1979, the Lupus Foundation of Florida has been serving Floridians affected by lupus. We are part of the Lupus Research Institute National Coalition whose funding of novel research brings the day closer when we can say, there is "Life without Lupus." Visit our website at www.lupusflorida.org.


'/>"/>
SOURCE Lupus Foundation of Florida
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. New Published Guidelines to Help Physicians Diagnose and Treat Lupus Kidney Disease
2. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
3. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
6. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
7. Two Of The Nations Top Specialists In Lupus, Drs. Swamy Venuturupalli & Daniel Wallace, Join In Expanding Research On Auto-Immune Diseases
8. For the Treatment of Lupus, the Emerging Therapies Epratuzumab and Lupuzor Have the Potential to Offer Improvements Over IV Belimumab in Reducing Disease Activity
9. American Academy of Family Physicians Foundation Launches Cities for Life
10. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
11. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ... a number of ,world firsts,: , TwinLink™ ...
Breaking Medicine Technology:
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... for human induced pluripotent stem (iPS) cells and other difficult to transfect cells, ... Cloning Medium. The PluriQ™ G9™ Gene Editing System is a complete ...
Breaking Medicine News(10 mins):